Pharmaceutical products
Original title: Open-House-Biologika-Rabattverträge 2025-19 - Adalimumab
| Country | Germany |
|---|---|
| Deadline | 2026-12-31 (40 days left) |
| Published | 2026-11-18 |
| Sectors | Health & life sciences |
| Source | TED - Tenders Electronic Daily (EU) |
Summary
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Adalimumab im Rahmen eines Open-House-Verfahrens.
The buyer, the value, the full description and the link to the official notice are available with a free account.